ANTIANGINAL MEDICAL THERAPY IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE REFERRED FOR CORONARY REVASCULARIZATION  by Mody, Purav et al.
Stable Ischemic Heart Disease
A1570
JACC April 1, 2014
Volume 63, Issue 12
antianginal medical theraPy in Patients With chronic ischemic heart disease referred 
for coronary revascUlarization
Poster Contributions
Hall C
Saturday, March 29, 2014, 3:45 p.m.-4:30 p.m.
Session Title: Old and Novel Therapies for Ischemic Heart Disease
Abstract Category: 26. Stable Ischemic Heart Disease: Therapy
Presentation Number: 1157-337
Authors: Purav Mody, Bertis Little, Rick Weideman, Emmanouil Brilakis, Subhash Banerjee, University of Texas Southwestern Medical Center, 
Dallas, TX, USA, VA North Texas Healthcare System, Dallas, TX, USA
Background: Given limited data for use of Ranolazine, an antianginal medication (AAM), following coronary revascularization for chronic ischemic 
heart disease (CIHD), we analyzed its use after percutaneous coronary interventions (PCI) and coronary artery bypass graft surgery (CABG).
methods: Among 3,613,031 patients with coronary artery disease, 78,706 with CIHD referred for PCI or CABG between 2005 and 2011 were 
included in the analysis. An AAM score was calculated based on drug classes and dose, and clinical outcomes (12-month death, non-fatal 
myocardial infarction or MI, and repeat revascularization or RR) were analyzed using Cox regression.
results: AAM scores in ranolazine treated (n=1,804) and untreated (n=76,902) were 4.0±0.07 and 2.3±0.01, respectively (p=0.001). Predictors 
of Ranolazine use are shown in Table 1. Ranolazine was added after significant escalation of AAM compared to the pre-PCI regimen. Despite greater 
comorbidity of Ranolazine treated patients, propensity adjusted and exact matched comparisons for death, MI and RR were similar to the untreated 
group.
conclusion: Ranolazine is predominantly prescribed to high-risk patients post coronary revascularization and is associated with similar 
cardiovascular outcomes compared to a lower-risk Ranolazine untreated group.
 
